ObesityNCT04037371
Environmental Temperature and Human White Adipose Tissue
An observational study of Obesity and Obesity, Abdominal, run by Petros Dinas at 1 site in Greece.
Trial summary
Obesity is characterized by excessive white adipose tissue (WAT) that increases risk for disease. About 700 million adults are obese worldwide, designating the need of reducing excessive WAT in humans and subsequently the risk for disease. Read more about this study
- Who is it for?
- Ages Up to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Obesity, Obesity, Abdominal, Obese
- What is being tested?
- Cold exposure
- How many people
- 20 participants
- Where
- 1 siteGreece
- Study dates
- 2 Apr 2017to 30 Mar 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 50 years
- Men only
- Healthy volunteers accepted
- Child, Adult
Study population: 20 healthy adult men [age: 36.30±5.33 (years); Body Mass Index: 28.46±5.49 (kg/m2)]
Who may be able to join
- healthy adult men
- no chronic disease
- not being under medication treatment
- non-smoking individuals
- non-regular exercisers individuals
Who cannot join
- non-adult men
- women
- chronic disease
- being under medication treatment
- smokers
- regular exercisers
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Environmental Temperature on Human White Adipose Tissue Thermogenic Capacity
Obesity is characterized by excessive white adipose tissue (WAT) that increases risk for disease. About 700 million adults are obese worldwide, designating the need of reducing excessive WAT in humans and subsequently the risk for disease. For this reason, previous research focused on the thermogenic capacity of white adipocytes in response to cold exposure. The investigators aimed to identify whether human WAT thermogenic activation could alter energy homeostasis and subsequently total body weight. The human WAT thermogenic capacity was assessed via Positron Emission Tomography/Computed Tomography (PET/CT) examination.
Read the detailed description
PET/CT cooling protocol Participants recruited through an advertisement in local newspapers or by word of mouth. An initial appointment was made to inform participants about the study and determine eligibility. A health pre-screening was done by interview through a suitable medical history questionnaire. The investigators obtained written consent from 20 healthy (no chronic disease and/or being under medication treatment) and non-smoking adult men [age: 36.30±5.33 (years); Body Mass Index: 28.46±5.49 (kg/m2)].
On the day of the measurements the participants advised to transport themselves by car to the PET/CT Laboratory at 07:30 am, following at least a 12-hour fasting. At 8 am the participants consumed a meal consisted of 50% carbohydrates, 20% proteins and 30% fat to avoid a thermic effect of food on white adipose tissue (WAT) activity. Also, to avoid a thermic effect of food on the Resting Energy Expenditure (REE) measurement, the caloric value of the meal was 15% of the total energy requirements of each participant. The total energy requirements was calculated following previous methodology. At 14:00 pm participants underwent measurements for body height using a Seca (Hamburg, Germany) stadiometer, body weight using a precision scale (KERN \& Sohn GmbH, Version 5.3, Germany) and Waist Hip Ratio using a tape measure. The investigators also measured blood pressure using a Standard Aneroid sphygmomanometer (Medisave, UK) according to standard guidelines. Blood glucose levels were determined via a Contour NEXT/ASCENSIA monitor. Participants who displayed blood glucose >140 mg/dl and blood pressure >140 mm/Hg were excluded from the study.
Immediately after the aforementioned measurements participants wore specific clothes (long-sleeve sweatshirt and sweatpants) that offered 0.49 clo insulation. Participants then undertook a REE assessment. Following the REE measurement participants remained in a sitting position in a cold room at 16-17ºC (humidity ~30-40%) for two hours. The room temperature and humidity were continuously monitored, while an investigator checked every 15 minutes participants muscle shivering status, according to previous methodology. The muscle shivering was tested using a scale, none (no tension of muscles reported), mild (slight muscle tonus in masseter muscle), moderate (real shivering in proximal muscles), severe (uncontrolled shivering in whole body). In case of moderate or severe shivering, participants were covered with a blanket for the next 15 minutes. After the first hour of cold exposure an appropriate dose - according to participants body weight - of F18 fludeoxyglucose (18F-FDG) was injected to the participants.
Following the 2-hour cooling protocol participants undertook the PET/CT examination. A Siemens Biograph 6 high resolution Erlangen Germany (2006) PET/CT was used to obtain images from the top of the skull to the upper third of the thigh. Six to eight bed positions (five minutes per bed position) were required.
White adipose tissue activity analysis WAT activity analysis (dorsolumbar region near vertebrae L3 and abdominal region) was performed by two independent trained physicians.
REE assessments for PET/CT cooling protocol REE assessments were conducted between 14:00 to 15:00 pm to comply with guidelines regarding the thermic effect of food on REE. The investigators have also instructed the participants to refrain from exercise, alcohol, and passive smoking in 72-hour prior to the measurements. REE was measured using an automated portable gas analyser (Oxycon Mobile, CareFusion, San Diego, USA) and the procedure was identical to the REE assessment for our UCP1 studies described above.
Environmental temperature (Tenv) recording Environmental data (ambient temperature) were obtained from Weather Underground (www.wunderground.com). Tenv was recording between January 2017 and March 2019. For the latter periods, the investigators obtained daily mean air temperature from the closest weather station operated near the area participants lived; the weather station Eleftherios Venizelos international station, Athens, Greece (37.93 °N, 23.93 °E) at an elevation of 94m.
- Conditions
- Obesity, Obesity, Abdominal, Obese
- Being tested
- Cold exposure
- Keywords
- Cold exposure, white fat cells, thermoregulation, winter
- Medical subject headings
- Obesity, Obesity, Abdominal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cold exposureOther
Participants were tested for white fat thermogenic activity against their environmental temperature exposure
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between white adipose tissue activity and environmental temperature. Mean differences in white adipose tissue activity between those participants who were assessed in winter and those who were assessed in summer.
White adipose tissue activity was assessed using a PET/CT examination to calculate the standardized uptake value (SUV) in dorsolumbar region near vertebrae L3 and abdominal region. Daily environmental temperature was obtained in degrees Celsius from the Weather Underground (www.wunderground.com) webpage for the period between January 2017 and February 2019
Measured: An overall of 10 hours of an assessment period that including two hours of cold exposure, 30 minutes of resting energy expenditure and 40 minutes of PET/CT assessments
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2019
- Study start2 Apr 2017
- Primary completion16 Jan 2018
- Study completion30 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Petros Dinas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Petros Dinas, University of Thessaly
- Investigators
- Andreas Flouris, PhD, Principal investigator, FAME Laboratory, Department of Exercise Science, University of Thessaly
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04037371
- Sponsor's protocol ID
- 1. PET/CT & Tenv
- Status last verified
- Jul 2019
- First submitted
- 22 Jul 2019
- Last updated
- 30 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Environmental Temperature on Human White Adipose Tissue Thermogenic Capacity
- ClinicalTrials.gov ID
- NCT04037371
- Acronym / sponsor ID
- 1. PET/CT & Tenv
- Conditions
- Obesity, Obesity, Abdominal, Obese
- Keywords
- Cold exposure, white fat cells, thermoregulation, winter
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Petros DinasUniversity, hospital or other
- Study start
- 2 Apr 2017 (actual)
- Primary completion
- 16 Jan 2018 (actual)
- Study completion
- 30 Mar 2018 (actual)
- First posted
- 30 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is characterized by excessive white adipose tissue (WAT) that increases risk for disease. About 700 million adults are obese worldwide, designating the need of reducing excessive WAT in humans and subsequently the risk for disease. For this reason, previous research focused on the thermogenic capacity of white adipocytes in response to cold exposure. The investigators aimed to identify whether human WAT thermogenic activation could alter energy homeostasis and subsequently total body weight. The human WAT thermogenic capacity was assessed via Positron Emission Tomography/Computed Tomography (PET/CT) examination.
Detailed description
PET/CT cooling protocol Participants recruited through an advertisement in local newspapers or by word of mouth. An initial appointment was made to inform participants about the study and determine eligibility. A health pre-screening was done by interview through a suitable medical history questionnaire. The investigators obtained written consent from 20 healthy (no chronic disease and/or being under medication treatment) and non-smoking adult men [age: 36.30±5.33 (years); Body Mass Index: 28.46±5.49 (kg/m2)].
On the day of the measurements the participants advised to transport themselves by car to the PET/CT Laboratory at 07:30 am, following at least a 12-hour fasting. At 8 am the participants consumed a meal consisted of 50% carbohydrates, 20% proteins and 30% fat to avoid a thermic effect of food on white adipose tissue (WAT) activity. Also, to avoid a thermic effect of food on the Resting Energy Expenditure (REE) measurement, the caloric value of the meal was 15% of the total energy requirements of each participant. The total energy requirements was calculated following previous methodology. At 14:00 pm participants underwent measurements for body height using a Seca (Hamburg, Germany) stadiometer, body weight using a precision scale (KERN \& Sohn GmbH, Version 5.3, Germany) and Waist Hip Ratio using a tape measure. The investigators also measured blood pressure using a Standard Aneroid sphygmomanometer (Medisave, UK) according to standard guidelines. Blood glucose levels were determined via a Contour NEXT/ASCENSIA monitor. Participants who displayed blood glucose >140 mg/dl and blood pressure >140 mm/Hg were excluded from the study.
Immediately after the aforementioned measurements participants wore specific clothes (long-sleeve sweatshirt and sweatpants) that offered 0.49 clo insulation. Participants then undertook a REE assessment. Following the REE measurement participants remained in a sitting position in a cold room at 16-17ºC (humidity ~30-40%) for two hours. The room temperature and humidity were continuously monitored, while an investigator checked every 15 minutes participants muscle shivering status, according to previous methodology. The muscle shivering was tested using a scale, none (no tension of muscles reported), mild (slight muscle tonus in masseter muscle), moderate (real shivering in proximal muscles), severe (uncontrolled shivering in whole body). In case of moderate or severe shivering, participants were covered with a blanket for the next 15 minutes. After the first hour of cold exposure an appropriate dose - according to participants body weight - of F18 fludeoxyglucose (18F-FDG) was injected to the participants.
Following the 2-hour cooling protocol participants undertook the PET/CT examination. A Siemens Biograph 6 high resolution Erlangen Germany (2006) PET/CT was used to obtain images from the top of the skull to the upper third of the thigh. Six to eight bed positions (five minutes per bed position) were required.
White adipose tissue activity analysis WAT activity analysis (dorsolumbar region near vertebrae L3 and abdominal region) was performed by two independent trained physicians.
REE assessments for PET/CT cooling protocol REE assessments were conducted between 14:00 to 15:00 pm to comply with guidelines regarding the thermic effect of food on REE. The investigators have also instructed the participants to refrain from exercise, alcohol, and passive smoking in 72-hour prior to the measurements. REE was measured using an automated portable gas analyser (Oxycon Mobile, CareFusion, San Diego, USA) and the procedure was identical to the REE assessment for our UCP1 studies described above.
Environmental temperature (Tenv) recording Environmental data (ambient temperature) were obtained from Weather Underground (www.wunderground.com). Tenv was recording between January 2017 and March 2019. For the latter periods, the investigators obtained daily mean air temperature from the closest weather station operated near the area participants lived; the weather station Eleftherios Venizelos international station, Athens, Greece (37.93 °N, 23.93 °E) at an elevation of 94m.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- Up to 50 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- 20 healthy adult men [age: 36.30±5.33 (years); Body Mass Index: 28.46±5.49 (kg/m2)]
Key inclusion criteria (5 listed)
- healthy adult men
- no chronic disease
- not being under medication treatment
- non-smoking individuals
- non-regular exercisers individuals
Key exclusion criteria (6 listed)
- non-adult men
- women
- chronic disease
- being under medication treatment
- smokers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cold exposureParticipants were tested for white fat thermogenic activity against their environmental temperature exposure | Other | – |
Primary outcome
Correlation between white adipose tissue activity and environmental temperature. Mean differences in white adipose tissue activity between those participants who were assessed in winter and those who were assessed in summer.
Time frame: An overall of 10 hours of an assessment period that including two hours of cold exposure, 30 minutes of resting energy expenditure and 40 minutes of PET/CT assessments
White adipose tissue activity was assessed using a PET/CT examination to calculate the standardized uptake value (SUV) in dorsolumbar region near vertebrae L3 and abdominal region. Daily environmental temperature was obtained in degrees Celsius from the Weather Underground (www.wunderground.com) webpage for the period between January 2017 and February 2019
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Obesity
Active, not recruiting
Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial
Bariatric Surgery Candidate, Obesity
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Not yet recruitingPhase 1
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Healthy Participants
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Obese Adults
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Flouris, PhD principal investigator
FAME Laboratory, Department of Exercise Science, University of Thessaly
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Obesity, Abdominal, run by Petros Dinas at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between white adipose tissue activity and environmental temperature. Mean differences in white adipose tissue activity between those participants who were assessed in winter and those who were assessed in summer. (time frame: An overall of 10 hours of an assessment period that including two hours of cold exposure, 30 minutes of resting energy expenditure and 40 minutes of PET/CT assessments). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2019.